Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04739865

Organisation Name: COMPASS Pathways

Overal Status: Recruiting

Start Date: September 15, 2020

Last Update: March 11, 2021

Lead Sponsor: COMPASS Pathways

Brief Summary: A recent open label study of the effects of psilocybin in participants with treatment-resistant depression (TRD) showed rapid significant decrease of depressive symptoms after treatment with psilocybin coupled with psychological support. Over 40% of participants sustained response at 3 months. In this study, the aim is to explore effectiveness of 25 mg of psilocybin as an adjunctive therapy in participants with TRD.

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 0.54232692718506